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RESULT: 40 patients were studied including 31 male and 9 female 
with average of 14.7 ± 3.8 years in case group and 16.2 ± 8.4 in 
control group. The mean disease duration in case group was 3.5 ± 3.2 
years and in control group was 15 ± 4.6. Comparing the severity of 
complaints and symptoms two weeks after treatment in two groups, 
there was a statistically significant difference in the tearing (p = 
0.029) and the size of papillae (p = 0.006). There wasn’t significant 
difference on other complaints and symptoms between two groups 
and no adverse effects of treatment with Mitomycin-C were 
observed. 
CONCLUSION: This study showed that use of topical mitomycin-C 
0.01% along with usual routine drugs reduces the severity of tearing 
and the size of papillae and it may be considered as a conventional 
treatment on patients with severe V.K.C.
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INTRODUCTION
Seasonal conjunctivitis is the most severe form of allergic 
conjunctivitis which is mostly seen in young men. The main 
immunological mechanism is unknown[1-2]. The prevalence of 
vernal keratoconjunctivitis (V.K.C) in a study conducted by 
Leonard et al. was estimated as 7.8 per 100,000 that was more 
prevalent among young men than young women[3].
    Sacchetti and et al in a study stated that the quality of life in 
children can be directly correlated with the prevalence of V.K.C 
in them[4]. Also Kumar et al. discussed about new therapeutic 
approaches for the management of vernal keratoconjunctivitis in 
children[5]. The disease is usually self-limiting but sometimes they 
are more serious and their control is difficult. If the symptoms are 
not limited by themselves or cause pain to the patient, medicine is 
prescribed that include mast cell stabilizers and steroids. Symptoms 
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ABSTRACT
BACKGROUND: Corticosteroids and mast–cell stabilizers are 
commonly used in treatment of vernal keratoconjunctivitis (V.K.C), 
but regarding the side – effects of the agents and poor response in 
severe cases, the aim of this study was to investigate the effect of low 
dose topical mitomycin- c 0.01% in the treatment of severe vernal 
keratoconjunctivitis.
METHODS: In a double blind randomized clinical trial, 40 patients 
with V.K.C were randomly assigned to two equal size groups. 
One group received topical 0.01% Mitomycin-C and another 
group received placebo. Complaints (tearing, itching, and mucosal 
discharge) and symptoms (papillae, Micropannus, hyper injection, 
corneal and limbus involvement) were assessed at the baseline and 2 
weeks after treatment in two groups. Data were analyzed by statistical 
methods in SPSS.16.
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can be seen in all seasons, but are more intense in spring and 
summer[6]. Corneal complications are often problematic for people 
suffering from the disease. A group of drugs that are commonly used 
to treat the disease are corticosteroids and mast cell stabilizers that 
steroids lead to many complications such as cataracts, glaucoma, 
increased intraocular pressure, infection and others. Therefore using 
an alternative, effective and safe medicine to control the disease 
can greatly reduce complications and blindness caused by the 
complications of the disease.
    VKC is a disease showing great racial and geographical variation. 
It is most common and most severe in hot, arid environments such as 
the Mediterranean basin, West Africa, and the Indian subcontinent. 
Patients with VKC generally present in early to mid-childhood. 
Patients from age 1 to 22 years old (mean 6 ± 3.7 years) may present 
with signs and symptoms of VKC[7].
    Mitomycin C is used to inhibit the cell proliferation and in addition 
to its usage in pterygium and glaucoma surgery, it has been used 
in the treatment of many patients with conjunctiva and corneal 
epithelium cancers[8-13]. The aim of this study was to evaluate the 
effect of mitomycin-C 0/01% in treatment of severe resistant to 
treatment V.K.C.
METHODS
This is a double blind clinical trial study that was conducted on 40 
patients with resistant to treatment V.K.C. Inclusion criteria were: no 
corneal epithelial defects, lack of eye disease and exclusion criteria 
were increasing the severity of the disease and side effects during 
the study period. Characteristics of complaints (itching, tearing 
and eye discharge) and signs (corneal involvement, micropannus, 
edemalimbus, papilla, and the congestion) of the disease were 
measured by clinical examinations and entered in checklists before, 
during and after study periods. It should be noted that the rater was 
not familiar with the classification of the groups. The case group 
treated with low dose topical mitomycin-c along with other eye drops 
such as Nephazoline, Antazoline,betamethasone and Cromolyn. In 
the control group over a period of two weeks, normal saline was 
used as placebo along with other eye-drops. The collected data were 
analyzed using statistical methods in SPSS.16.
RESULT
SOf all patients, 31 (77.5%) were male and 9 (22.5%) were female. 
The mean age of the case group and control group was 13.8 ± 2.7 
and 8.4 ± 3.2, respectively. The mean duration of illness in case 
group patients was 3.2 ± 3.5 years and in control group patients 
was 4.5 ± 4.6. Of all patients, 7 (17.5%) had a history of seasonal 
allergy and allergic which 4 patients (57.1%) in the control group 
and 3(42.9%) in case group. Of all patients, 4(10%) had a positive 
family history. All studied patients complained of itching and most 
of them (34 patients) had high level (severe, very severe) of itching. 
After completing the course of treatment, significant improvement 
was observed in both case and control groups. (p = 0.001) In the 
case group, 1 patient and in the control group 4 patients complained 
about intense itching after two weeks. By clinically examination we 
showed that, 100% of patients in the case group and 95% of patients 
in the control group had medium to high degrees of eye congestion 
before entering the study. At the end of the treatment in the case 
group, 80% of patients have mild degree of eye congestion and 20% 
had moderate to severe eye congestion. (p = 0.001) In the control 
group, after 2 weeks of using previous common drugs associated 
with normal saline, 45% of patients had mild, 45% moderate and 
10% severe eye congestion degree, respectively, and eye congestion 
had not been completely cut off in none of the patients. (p = 0.045) 
Before treatment, 70 percent in the case group and 65 percent of 
patients in the control group had macro papilla. The Papilla size 
change rate in two groups was statistically significant difference after 
treatment. (p=0.006) Before treatment, 40% in the case group and 
50% in the control group had no corneal involvement and the most 
prevalent type of involvement in each group was infiltration and 
Pigment epithelial detachment (PED), respectively, each with 30%. 
The difference was not significant between the two groups in terms 
of involvement. In the case group 25 % of patients and in the control 
group 35% of patients had micropannus before entering the study. 
After two weeks treatment, this rate declined to 5% in the case group 
and 15% in the control group, respectively and this reduction rate 
wasn’t significant between two groups (Table 1).
DISCUSSION
The study showed a significant difference between the groups 
in terms of tearing so that improvement in the case group was 
significantly higher than the control group (p = 0.029). In 
Memarzadeh and Emad studies, tearing had a significant reduction 
after taking mitomycin-C[1,14]. In studies conducted in other places 
it was found that, compared to steroids, mitomycin-C wasn’t more 
effective in tearing improvement[15-16]. 
    The results of our study showed that the recovery rate and 
reduction the severity of itching in the patients of the case group 
was higher compared to the control group but was not statistically 
significant.However in the studies conducted in other places, the 
recovery rate and reduction of the severity of itching in the case 
group compared to the control group had significant difference[1,14].
    Other examined complaint was the patients’ eye discharge that 
there was no significant difference between the two groups but the 
rate of improvement was greater in the case group than control 
group. In a study conducted by Jain[16], mitomycin-c was better in 
improving three of the symptoms and complaints of V.K.C including 
eye discharge than steroids.
    In this study, a significant difference (p = 0.006) was observed 
among the patients in terms of reducing the size of the papilla 
between the two groups before and after treatment. In studies done 
in other places, although most of the complaints and symptoms had 
decreased, but there was no difference between the two groups in 
terms of papilla size change[1,14].
    In this study, by clinically examined we showed that reducing the 
severity of eye congestion (Ocular congestion) in patients who were 
Table 1 Severity of complaints and symptoms in two groups before and 
after treatment.
Groups Mitomycin-C (n = 20) Placebo (n = 20) p-value
Before After Before After
Variables n(%) n(%) n(%) n(%)
Complaints
Tearing 18(90) 7(35) 18(90) 15(75) 0.029
Itching 20(100) 15(75) 20(100) 18(90) 1
Severe eye congestion 15(75) 1(5) 15(75) 2(10) 0.23
Discharge 14(70) 1(5) 14(70) 5(25) 1
Symptoms
Limbal edema 8(40) 1(5) 7(35) 3(15) 0.74
Micropannus 5(25) 1(5) 7(35) 3(15) 0.49
Cornel involvement 12(60) 4(20) 10(50) 9(45) 0.29
Macro-papillae 14(70) 9(45) 13(65) 15(75) 0.006
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treated with Mitomycin-C was higher than patients who were treated 
with normal saline but the difference was not statistically significant. 
In Jain’s study, mitomycin-C has been reported as an effective drug 
in reducing the eye congestion in the treatment of severe V.K.C.
    Other symptoms that were evaluated in this study in patients 
before and after treatment are: Corneal involvement, micropannus 
and limbal edema. In these cases in the case group compared to the 
control, a noticeable improvement of symptoms was observed but not 
significant.
     In studies done in other places, the above mentioned 
symptoms had a remarkably good response to treatment with 
mitomycin-C[1,5,13-14]. Also in the study conducted by Jain and Akpek 
et al[16-17], limbal edema has been substantially improved with the 
use of mitomycin-C in comparison with steroids. The reason for 
the difference between the results of this study with the mentioned 
studies can be probably due to the small sample size in this study 
compared to other studies.
    Kumar in a study showed that the Cyclosporine has been shown to 
be effective in the treatment of VKC but further randomized control 
trials are required to establish the minimum effective concentration[18].
    Similar to our study, Al-Okour and et al in study showed that 72 
(58.5%) of patients with VKC were males and average of 9.9 years. 
Severe vernal keratoconjunctivitis was seen in 31 (25.2%) patients: 
16 (13%) patients of mixed type, 9 (7.3%) of limbal type, and 6 
(4.9%) of palpebral type[19].
    Mantelli et al showed that all topical drugs such as Mitomycin-c 
are effective in the treating acute phases of VKC and also showed 
significant improvement in all signs and symptoms, except 
photophobia in all groups which was in line with our study results[20].
CONCLUSION
The results showed that the use of topical mitomycin-C drop along 
with routine drugs significantly can be effective in reducing the size of 
the papilla and tearing. Also the use of topical mitomycin C compared 
to the drop of normal saline, tend to reduce complaints (ocular 
discharge and itching) and signs (hyperemia, limbal edema, corneal 
involvement and micropannus) in patients. Doing multi-center study 
in different parts of the country should be performed in future.
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